Catherine Pemberton-Ross

Title: Catherine Pemberton-Ross: Innovator in Tumor Antigen Research

Introduction

Catherine Pemberton-Ross is a notable inventor based in Otelfingen, Switzerland. She has made significant contributions to the field of cancer research, particularly in the development of antibodies targeting tumor antigens. Her work is crucial for advancing treatment and diagnostic methods for solid tumors.

Latest Patents

Catherine holds a patent for "Antibodies to tumour antigens." This patent focuses on specific binding members that target carbonic anhydrase IX (CAIX). The application details methods for the treatment, diagnosis, and detection of tumors using these specific binding members. Additionally, these members can be conjugated to biocidal or cytotoxic molecules, or to detectable labels, enhancing their utility in clinical settings.

Career Highlights

Catherine is currently associated with Philogen S.p.a., a company known for its innovative approaches in biopharmaceuticals. Her work at Philogen has positioned her as a key player in the development of targeted therapies for cancer.

Collaborations

Catherine collaborates with talented professionals in her field, including Laura Gualandi and Sarah Wulhfard. These partnerships enhance the research and development efforts at Philogen, fostering an environment of innovation and discovery.

Conclusion

Catherine Pemberton-Ross is a pioneering inventor whose work in tumor antigen research is making a significant impact in the medical field. Her contributions are vital for the future of cancer treatment and diagnosis.